Natural History of Aerosol-Induced Ebola Virus Disease in Rhesus Macaques

Abstract

Ebola virus disease (EVD) is a serious global health concern because case fatality rates are approximately 50% due to recent widespread outbreaks in Africa. Well-defined nonhuman primate (NHP) models for different routes of Ebola virus exposure are needed to test the efficacy of candidate countermeasures. In this natural history study, four rhesus macaques were challenged via aerosol with a target titer of 1000 plaque-forming units per milliliter of Ebola virus. The course of disease was split into the following stages for descriptive purposes: subclinical, clinical, and decompensated. During the subclinical stage, high levels of venous partial pressure of carbon dioxide led to respiratory acidemia in three of four of the NHPs, and all developed lymphopenia. During the clinical stage, all animals had fever, viremia, and respiratory alkalosis. The decompensatory stage involved coagulopathy, cytokine storm, and liver and renal injury. These events were followed by hypotension, elevated lactate, metabolic acidemia, shock and mortality similar to historic intramuscular challenge studies. Viral loads in the lungs of aerosol-exposed animals were not distinctly different compared to previous intramuscularly challenged studies. Differences in the aerosol model, compared to intramuscular model, include an extended subclinical stage, shortened clinical stage, and general decompensated stage. Therefore, the shortened timeframe for clinical detection of the aerosol-induced disease can impair timely therapeutic administration. In summary, this nonhuman primate model of aerosol-induced EVD characterizes early disease markers and additional details to enable countermeasure development.

A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure

“…with a target dose of 1,000 PFU (plaque-forming units) of SUDV/Bon, SUDV/Gulu or EBOV/Kik in a volume of 1mL. For aerosol challenge, NHPs were exposed to a target dose of 100 PFU in a head-only chamber in a class III biological safety cabinet connected to the BSL-4 as previously described ( 38, 39 ). During the challenge studies, blood was collected from the NHPs for hematological, biochemical and virological analyses as previously described ( 10, 32 ).…”

CRISPR-Cas13: A new technology for the rapid detection of pathogenic microorganisms

“…In addition, as of September 2021, the cumulative number of confirmed infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) globally has exceeded 225 million, and the associated disease, COVID-19, has caused more than 4.6 million deaths. 1 The curbing of the spread of these two viruses has been challenging, especially as both viruses have been shown to be transmittable via aerosols ( van Doremalen et al, 2020 ; Downs et al, 2021 ). The transmission of bacteria, viruses, and other pathogenic microorganisms can occur in multiple ways, such as contact with surfaces or the air or even through the food chain and water reservoirs ( Szewzyk et al, 2000 ).…”